• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

    2/26/24 9:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families

    MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world.

    In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families (CNW Group/Alexion)

    Approximately, three million – or one in 12 – Canadians and their families face a debilitating disease that severely impacts their lives.i colourUp4RARE is an opportunity for people across the country and around the world to share their colours by making their mark on a zebra, the long-time symbol for rare diseases, and help bring visibility to rare diseases.

    From now until March 3, 2024 on www.colourUp4RARE.com, Canadians can colour in the stripes of a digital zebra in the Rare Disease Day colours – blue, green, pink and purple – in support of people living with rare diseases and their families, and to highlight the importance of research for new diagnostic and treatment options.

    Worldwide, around 7,000 rare diseases are known so far, with more being discovered each year.ii More than 90 per cent of all rare diseases do not have an approved treatment iii and only 60 per cent of approved treatments make it into Canada, up to six years later than in the USA and Europe.iv It takes an average of 4.8 years for people with rare diseases to receive an accurate diagnosis v and one in four children with a rare disease will not live to see their tenth birthday.vi 

    "At Alexion, we stand with patients, families and communities affected by rare diseases," says Gaby Bourbara, Vice President and General Manager, Alexion Canada. "On Rare Disease Day, we are reminded of the strides we have made in understanding and treating rare diseases but recognize there is still much to be done. In 2023, Canada announced its first national rare disease strategy, however, little has been done to alleviate the suffering of millions of patients living with rare diseases and their caregivers. colourUp4RARE is part of our commitment to bringing hope and transformative therapies to those who face the greatest challenges and to advocate on behalf of all rare disease patients in Canada."

    "Despite their name, rare diseases aren't really that rare – more than 300 million people are living with a rare disease worldwide," says Durhane Wong-Rieger, president and CEO, Canadian Organization for Rare Disorders (CORD). "This campaign creates a unique, rallying moment that raises awareness for those living with rare diseases and their families. CORD and the rare disease community benefit from these initiatives and partners like Alexion as we move to implement the national strategy on rare disease and the Rare Disease Network. We need to call for urgent access to life-altering treatments on behalf of all Canadians living with a rare disease." 

    "When you hear hoofbeats, think of zebras, not horses," adds Jonathan Pratt, Directeur general, Regroupment Québécois des Maladies Orphelines (RQMO). "By coming together across Canada and around the world – united by the image of the zebra – we aim to make rare diseases more visible and drive action to expand access to diagnosis and treatment to improve quality of life."

    colourUp4RARE is an international, collaborative campaign spearheaded by Alexion and supported by CORD and RQMO on behalf of Canadians affected by rare diseases. To learn more and join the challenge, please visit www.colourUp4RARE.com.

    Alexion

    Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for more than 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Please visit https://alexion.com/worldwide/canada.

    AstraZeneca

    AstraZeneca (NASDAQ:AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca.ca and follow the Company on X @AstraZenecaCA.

    Canadian Organization for Rare Disorders (CORD)

    CORD is Canada's national network for organizations representing all those with rare disorders. CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders. CORD works with governments, researchers, clinicians and industry to promote research, diagnosis, treatment and services for all rare disorders in Canada. For more information, visit www.raredisorders.ca.

    Quebec Coalition of Orphan Diseases

    RQMO is a non-profit organization whose mission is to inform and educate while providing support to patients suffering from rare and orphan diseases, as well as their families and health professionals through its iRARE center, an information and support center for rare diseases, a unique resource in Canada. The RQMO unites 34 rare disease associations, together with individuals with a rare disease and family members or caregivers of individuals, raises awareness on rare diseases for the general population as well as the medical community and works to advance knowledge and research by facilitating collaboration between patients and researchers.

    References


    __________________________________________

    i
    Canadian Organization for Rare Disorders (CORD). https://www.raredisorders.ca/about-cord/. Accessed January 18, 2024.



    ii Haendel, M., Vasilevsky, N., Unni, D., Bologa, C., Harris, N., Rehm, H., Hamosh, A., Baynam, G., Groza, T., McMurry, J., Dawkins, H., Rath, A., Thaxon, C., Bocci, G., Joachimiak, M.P., Köhler, S., Robinson, P.N., Mungall, C. and Oprea, T.I. (2020). How many rare diseases are there? Nature Reviews Drug Discovery, [online] 19(2), pp.77–78. doi: 10.1038/d41573-019-00180-y.



    iii National Organization for Rare Disorders (NORD). New Report Finds Medical Treatments for Rare Diseases Account for Only. 11% of US Drug Spending; Nearly 80% of Orphan Products Treat Rare Diseases Exclusively. https://rarediseases.org/new-report-finds-medical-treatments-for-rare-diseases-account-for-only-11-of-us-drug-spending-nearly-80-of-orphan-products-treat-rare-diseases-exclusively/. Accessed January 18, 2024.



    iv Canadian Organization for Rare Disorders (CORD). https://www.raredisorders.ca/about-cord/. Accessed January 18, 2024.



    v Global Genes. (n.d.). RARE Disease Facts. [Online] Available at: https://globalgenes.org/rare-disease-facts/.



    vi Canadian Organization for Rare Disorders (CORD). https://www.raredisorders.ca/about-cord/. Accessed January 18, 2024.

    SOURCE Alexion

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2024/26/c8798.html

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

      AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positi

      5/7/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results will be shared with regulatory authorities Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients w

      5/7/25 2:30:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

      Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI as a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRI versus maintenance

      5/2/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/4/22 9:06:48 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/3/21 1:13:21 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Financials

    Live finance-specific insights

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • AstraZeneca's Full Year and Q4 2024 results

      Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

      2/6/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/6/25 9:15:27 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/2/25 9:38:38 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

      In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

      2/26/24 9:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care